nivolumab,brentuximab,doxorubicin hydrochloride,dacarbazine,filgrastim,pegfilgrastim,vinblastine sulfate
seagen,bms,amgen
[]
adverse events:
less peripheral neuropathy (55% vs 29%) with n-avd than with bv-avd similar febrile neutropenia (5% vs 7%) despite 54% gcsf in n-avd and 95% gcsf in bv-avd - important given given bone pain can be substantial younger patients #asco23 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem